Novo Nordisk to unveil major diabetes & obesity data at ADA 2025

DENMARK—Novo Nordisk is set to showcase new data from its leading metabolic and cardiovascular health portfolio at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions, scheduled for June 20–23, 2025, in Chicago, USA.

The company will present 29 abstracts covering a range of studies, including trials on a higher dose of Wegovy® (semaglutide 7.2 mg) aimed at people with obesity who require greater weight loss.

These include the STEP UP trial for obesity and the STEP UP T2D trial for those with both obesity and type 2 diabetes, offering a new treatment option for more significant weight reduction.

In addition to weight loss data, Novo Nordisk will present further evidence on the cardiovascular and kidney health benefits of semaglutide for people with type 2 diabetes.

This will include analyses from the SOUL, STRIDE, and FLOW trials, as well as insights from real-world studies involving semaglutide 2.4 mg.

These findings reinforce the role of semaglutide in improving broader health outcomes beyond glucose control.

A highlight of the presentations will be the first-ever Phase 3 data from the CagriSema REDEFINE 1 and 2 trials.

CagriSema is an investigational combination of GLP-1 and amylin receptor agonists, which holds promise for transformational effects in treating overweight and obesity, including in patients with type 2 diabetes.

This novel approach underscores Novo Nordisk’s commitment to innovation in obesity care.

Moreover, data on amycretin, a pipeline candidate, will be shared, further demonstrating the company’s dedication to advancing personalized healthcare solutions for obesity and related metabolic diseases.

On June 22, Novo Nordisk will host an R&D investor event to discuss the science and abstracts presented at the congress, focusing on their metabolic and cardiovascular health portfolio.

This event will be accessible via a live webcast, allowing broader engagement with the latest research developments.

Ludovic Helfgott, Executive Vice President of Product & Portfolio Strategy at Novo Nordisk, emphasized their goal to meet individual health needs by offering a higher dose of Wegovy for those requiring more substantial weight loss.

He highlighted semaglutide’s comprehensive, disease-modifying effects across metabolic and cardiovascular health and expressed optimism that the data presented at ADA 2025 for Wegovy®, Rybelsus®, and Ozempic® will strengthen its role as a foundational therapy providing early and broad protection.

Martin Holst Lange, Executive Vice President for Development, highlighted the complex relationship between cardiovascular and metabolic diseases such as type 2 diabetes and obesity, which necessitates personalized treatment approaches.

He added that the ADA 2025 data not only show how Novo Nordisk is currently addressing a wide range of patient needs with semaglutide but also reflect ongoing investments in innovation to support people living with serious chronic diseases.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.